Concept
It’s now easy to extrapolate that on some time-scale we’re headed to end-to-end autonomous hypothesis generation, execution, and adaptive learning to feedback results to improved experimentation.
Longer Description
We're now seeing the emergence of fully autonomous systems that can design, conduct, and iterate on experiments with minimal human intervention. There have been closed loop systems developed by organizations like Deepmind (A-Lab) and some for-profit endeavors in chemistry with Chemify and to a lesser degree Bullseye Bio. Some autonomous research capabilities have passed the Rubicon of materials science and chemistry to biology with encouraging work on autonomous exploration of biological systems.
Likely a venture-scale company will have a variety of principles including:
- Multi-modal AI Integration: Combining large language models for reasoning and planning with specialized AI models for specific scientific tasks (e.g., molecular property prediction, reaction outcome prediction).
- Adaptive Learning Systems: Developing AI that can quickly learn from experimental outcomes and adjust its strategies in real-time.
- Commercial systems expanding outside of chemistry and materials science to protein design and cellular engineering.
Potential Use-Cases:
- Rapid Response Platforms for Emerging Threats: Develop systems that can quickly pivot to address urgent research needs, such as designing antivirals for new pathogens or developing materials to capture novel pollutants.
- Enzyme Engineering for Industrial Biocatalysis: Expand on the protein engineering platform's work to engineer enzymes for specific industrial applications.
- Drug Discovery Optimization: Focus on optimizing lead compounds in pharmaceutical research. The system could autonomously explore chemical space to improve potency, selectivity, and ADME properties of potential drug candidates.
- Reaction Condition Optimization: Building on Coscientist's success, focus on optimizing reaction conditions for complex organic syntheses, particularly for reactions that are challenging to optimize manually (e.g., asymmetric catalysis, multicomponent reactions).
Other thoughts
- Terminal business model is not clear whether it’s best to be an infrastructure or fully verticalized company
- Founders should be deeply critical here whether they’re excellent at enterprise sales or not.
- Killer, creative use-cases needed in order to get wedge into the market.
- Initial capex might be higher but lower operating costs might even out.
Comparable Companies
Bullseye Bio
- using the PRANCE system
Related Reading
